Scholarlink

Background <p>The tumor immune microenvironment critically influences progression and therapeutic response in intrahepatic cholangiocarcinoma (ICC). MYBL2 drives tumor aggressiveness, while CCL5 regulates immune-cell recruitment; however, their combined impact on immune composition and PD-1 therapy response remains undefined.</p> Methods <p>Tumor specimens from 127 ICC patients were assessed by immunohistochemistry and whole-slide digital quantification. MYBL2 and CCL5 expression were classified into four combinatorial phenotypes. Associations with immune-cell infiltration, survival, and treatment response were evaluated using correlation analysis, Kaplan–Meier curves, Cox regression, and PD-1 interaction analyses. Seventy patients received adjuvant PD-1 therapy.</p> Results <p>MYBL2 and CCL5 expression were positively correlated (<i>r</i> = 0.38, <i>p</i> &lt; 0.001). Higher CCL5 levels were associated with increased CD163⁺ TAM density (<i>r</i> = 0.31, <i>p</i> &lt; 0.001) and a reduced CD8/CD163 ratio, indicating an immunosuppressive microenvironment. The MYBL2–CCL5 classification provided clear prognostic discrimination, with the Double-High subgroup showing the shortest OS and PFS. Among PD-1–treated patients, treatment benefit varied markedly across phenotypes: the Double-Low group achieved the greatest survival advantage, whereas the Double-High group showed minimal response, reflecting primary resistance. In multivariable analysis, Double-Low remained strongly protective compared with Double-High.</p> Conclusion <p>The MYBL2–CCL5 co-expression phenotype identifies an immunosuppressive, TAM-dominant microenvironment and serves as a dual biomarker for both prognosis and PD-1 treatment sensitivity in ICC. This immunologic classification offers a practical framework for postoperative risk stratification and personalized immunotherapy decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlated expression of MYBL2 and CCL5 defines an immunosuppressive microenvironment and predicts poor prognosis in intrahepatic cholangiocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Junkai Ren,
  • Sicheng Xu,
  • Xing He,
  • Huilin Ye,
  • Wenbin Li

摘要

Background

The tumor immune microenvironment critically influences progression and therapeutic response in intrahepatic cholangiocarcinoma (ICC). MYBL2 drives tumor aggressiveness, while CCL5 regulates immune-cell recruitment; however, their combined impact on immune composition and PD-1 therapy response remains undefined.

Methods

Tumor specimens from 127 ICC patients were assessed by immunohistochemistry and whole-slide digital quantification. MYBL2 and CCL5 expression were classified into four combinatorial phenotypes. Associations with immune-cell infiltration, survival, and treatment response were evaluated using correlation analysis, Kaplan–Meier curves, Cox regression, and PD-1 interaction analyses. Seventy patients received adjuvant PD-1 therapy.

Results

MYBL2 and CCL5 expression were positively correlated (r = 0.38, p < 0.001). Higher CCL5 levels were associated with increased CD163⁺ TAM density (r = 0.31, p < 0.001) and a reduced CD8/CD163 ratio, indicating an immunosuppressive microenvironment. The MYBL2–CCL5 classification provided clear prognostic discrimination, with the Double-High subgroup showing the shortest OS and PFS. Among PD-1–treated patients, treatment benefit varied markedly across phenotypes: the Double-Low group achieved the greatest survival advantage, whereas the Double-High group showed minimal response, reflecting primary resistance. In multivariable analysis, Double-Low remained strongly protective compared with Double-High.

Conclusion

The MYBL2–CCL5 co-expression phenotype identifies an immunosuppressive, TAM-dominant microenvironment and serves as a dual biomarker for both prognosis and PD-1 treatment sensitivity in ICC. This immunologic classification offers a practical framework for postoperative risk stratification and personalized immunotherapy decision-making.